A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer
Immunity, Inflammation and Disease · 2024
DOI: 10.1002/iid3.1348 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Chenyu Mao und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Gastrointestinal Neoplasms, Neutropenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Hengrui Medicine.
Abstract (Originalsprache)
Background
Mecapegfilgrastim, a long‐acting granulocyte‐colony stimulating factor has been approved for reducing the incidence of infection, particularly febrile neutropenia (FN), in China.
Objective
We conducted a multicenter prospective observational study to examine the safety and effectiveness of mecapegfilgrastim in preventing neutropenia in gastrointestinal patients receiving the chemotherapy, including S‐1/capecitabine‐based regimens or the fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) regimens.
Method
Five hundred and sixty‐one gastrointestinal patients from 40 sites across China, between May 2019 and November 2021, were included. The administration of mecapegfilgrastim was prescribed at the discretion of local physicians.
Results
The most common adverse drug reactions (ADRs) of any grade for all patients was increased white blood cells (2.9%). Grade 3/4 ADRs were observed for anemia (0.2%), decreased white blood cells (0.2%), and decreased neutrophil count (0.2%). Among the 116 patients who received S‐1/capecitabine‐based chemotherapy throughout all cycles, ADRs of any grade included anemia (1.7%), myalgia (0.9%), and increased alanine aminotransferase (0.9%). No grade 3/4 ADRs were observed. In 414 cycles of patients who underwent S‐1/capecitabine‐based regimens, only one (0.2%) cycle experienced grade 4 neutropenia. In the FOLFIRINOX, FOLFOXIRI, and FOLFOX chemotherapy regimens, grade 4 neutropenia occurred in one (2.7%) of 37 cycles, four (4.7%) of 85 cycles, and two (1.2%) of 167 cycles, respectively.
Conclusion
In a real‐world setting, mecapegfilgrastim has proven effective in preventing severe neutropenia in gastrointestinal patients following chemotherapy. This includes commonly used moderate or high‐risk FN regimens or regimens containing S1/capecitabine, all of which have demonstrated favorable efficacy and safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.
- Department of Oncology, The First People's Hospital of Changzhou, Changzhou, China.
- Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
- Department of Oncology, Bozhou People's Hospital, Bozhou, China.
- Department of Oncology, The Second People's Hospital of Changzho, Changzhou, China.
ORCID-Profile: Chenyu Mao, Yong Chen, Zhe Yang, Shukui Qin
Förderung
- Jiangsu Hengrui Medicine
Zitieren
APA
Mao, C., He, Y., Xu, N., Yan, H., Zhang, N., Cheng, G., Jiang, H., Chen, M., Chen, Y., Wang, X., Gu, Y., Shen, P., Zhang, G., Yan, J., Yang, Z., Ding, L., Han, Z., Wang, Z., Zhang, J., …, & Qin, S. (2024). A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1348
Vancouver
Mao C, He Y, Xu N, Yan H, Zhang N, Cheng G, et al. A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.1348
BibTeX
@article{Mao2024,
author = {Mao, Chenyu and He, Ye and Xu, Nong and Yan, Haijiao and Zhang, Ningling and Cheng, Gang and Jiang, Hua and Chen, Minbin and Chen, Yong and Wang, Xiaoguang and Gu, Yulan and Shen, Peng and Zhang, Guifang and Yan, Jun and Yang, Zhe and Ding, Lifang and Han, Zhengxiang and Wang, Zhanggui and Zhang, Junqi and Zheng, Weie and Wang, Jufeng and Qin, Shukui},
title = {A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer},
journal = {Immunity, Inflammation and Disease},
year = {2024},
doi = {10.1002/iid3.1348}
}
EUVIMED